Screener
Viridian Therapeutics, Inc. VRDN Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $8,652 | $8,683 |
| Accrued liabilities | 55,142 | 62,013 |
| Total current liabilities | 63,794 | 70,696 |
| Long-term debt, net | — | 49,940 |
| Derivative liability | 13,690 | 20,030 |
| Liability related to the sale of future revenue, net | 113,642 | 34,244 |
| Convertible notes, net | 242,159 | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Viridian Therapeutics, Inc.'s total current liabilities?
- Viridian Therapeutics, Inc. (VRDN) reported total current liabilities of $63.79M in Q2 2026.
- How has Viridian Therapeutics, Inc.'s total current liabilities changed year-over-year?
- Viridian Therapeutics, Inc.'s total current liabilities increased by 21.3% year-over-year, from $52.59M to $63.79M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s total current liabilities has grown at a 46.0% compound annual growth rate (CAGR), from $10.67M to $70.7M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Viridian Therapeutics, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude